Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size & Outlook, 2026-2034

Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Insights

Based on Reed Intelligence findings, the Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market reached USD 16.2 Million in 2025 and is estimated to attain USD 33.7 Million by 2034.
From 2026 to 2034, the Australia market is expected to grow at a steady CAGR of 8.41%.
Within the Drug Class category, Corticosteroids dominated in 2025 in terms of market size contribution.
Over the forecast period, Corticosteroids is forecasted to deliver the fastest growth, positioning it as the most lucrative Drug Class segment.

Other Key Findings

As of 2025, Australia held 1.12% of the global Eosinophilic Granulomatosis with Polyangiitis Treatment Market size.
By 2034, United States is anticipated to capture the largest share of the global Eosinophilic Granulomatosis with Polyangiitis Treatment Market.
In Asia Pacific, China is expected to lead the regional Eosinophilic Granulomatosis with Polyangiitis Treatment Market size by 2034.
South Korea will remain the fastest-growing market in Asia Pacific, reaching USD 34.79 Million by 2034.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 16.2 Million
Market Size In 2034	USD 33.7 Million
Largest segment	Corticosteroids
Units	Revenue in USD Million
CAGR	8.41% (2026-2034)
Segmnetation Covered
Drug Class	Corticosteroids Immunosuppressants Biologics
Route of Administration	Oral Injectable
End-Use	Hospitals Specialty Clinics Others
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drug Class 2026-2034 (USD Million)

Drug Class	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Corticosteroids	XX.x	XX.x	XX.x	8.83	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Immunosuppressants	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Biologics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Route of Administration 2026-2034 (USD Million)

Route of Administration	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Oral	XX.x	XX.x	XX.x	9.4	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Injectable	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market End-Use 2026-2034 (USD Million)

End-Use	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	7.56	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.